Drug discovery methods for studying brain drug delivery and distribution

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 10, Issue , 2014, Pages 271-316

  Loryan, Irena ^a   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85081145444     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9105-7_10     Document Type: Article

References (211)

1. Abbott NJ (2004) Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 45(4):545–552
2. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis 37(1):13–25
3. Abraham MH (2011) The permeation of neutral molecules, ions, and ionic species through membranes: brain permeation as an example. J Pharm Sci 100(5):1690–1701
4. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF (2012) Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-gp, BCRP, and P-gp/BCRP knockout mice. Drug Metab Dispos 40(6):1164–9
5. Banker MJ, Clark TH, Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92(5):967–974
6. Bean JW, Sargent DF, Schwyzer R (1988) Ligand/receptor interactions–the influence of the microenvironment on macroscopic properties. Electrostatic interactions with the membrane phase. J Recept Res 8(1–4):375–389
7. Becker S, Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos 34(5):855–861
8. Begley DJ (1996) The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48(2):136–146
9. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104(1):29–45
10. Bendayan R, Lee G, Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57(5):365–380
11. Benkwitz C, Liao M, Laster MJ, Sonner JM, Eger EI 2nd, Pearce RA (2007) Determination of the EC50 amnesic concentration of etomidate and its diffusion profile in brain tissue: implications for in vitro studies. Anesthesiology 106(1):114–123
12. Berry LM, Roberts J, Be X, Zhao Z, Lin MH (2010) Prediction of V(ss) from in vitro tissue-binding studies. Drug Metab Dispos 38(1):115–121
13. Blasberg R, Levi G, Lajtha A (1970) A comparison of inhibition of steady state, new transport, and exchange fluxes of amino acids in brain slices. Biochim Biophys Acta 203(3):464–483
14. Bostrom E, Simonsson US, Hammarlund-Udenaes M (2006) In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34(9):1624–1631
15. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M (2001) Blood–brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats–pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 134(8):1796–1804
16. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jaattela M, Kroemer G (2003) Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 197(10):1323–1334
17. Boya P, Kroemer G (2008) Lysosomal membrane permeabilization in cell death. Oncogene 27(50):6434–6451
18. Brunner D, Balci F, Ludvig EA (2012) Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration. Behav Processes 89(2):187–195
19. Bundgaard C, Jensen CJ, Garmer M (2012a) Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice. Drug Metab Dispos 40(3):461–466
20. Bundgaard C, Jorgensen M, Mork A (2007) An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. J Pharmacol Toxicol Methods 55(2):214–223
21. Bundgaard C, Sveigaard C, Brennum LT, Stensbol TB (2012b) Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: the role of free drug concentrations. Xenobiotica 42(3):256–265
22. Chesney MA, Perouansky M, Pearce RA (2003) Differential uptake of volatile agents into brain tissue in vitro. Measurement and application of a diffusion model to determine concentration profiles in brain slices. Anesthesiology 99(1):122–130
23. Collingridge GL (1995) The brain slice preparation: a tribute to the pioneer Henry McIlwain. J Neurosci Methods 59(1):5–9
24. Cserr HF, Patlak CS (1992) Secretion and bulk flow of interstitial fluid. In: Bradbury MWB (ed) Physiology and pharmacology of the blood–brain barrier. Springer, Berlin, pp 245–261
25. Dagenais C, Zong J, Ducharme J, Pollack GM (2001) Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res 18(7):957–963
26. Daniel WA (2003) Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry 27(1):65–73
27. Daniel WA, Bickel MH, Honegger UE (1995) The contribution of lysosomal trapping in the uptake of desipramine and chloroquine by different tissues. Pharmacol Toxicol 77(6):402–406
28. Daniel WA, Syrek M, Haduch A, Wojcikowski J (1998) Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine. Pol J Pharmacol 50(6):431–442
29. Daniel WA, Syrek M, Haduch A, Wojcikowski J (2000) Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. J Pharm Pharmacol 52(12):1473–1481
30. Daniel WA, Wojcikowski J (1997) Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol 80(2):62–68
31. Daniel WA, Wojcikowski J (1999a) Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur Neuropsychopharmacol 9(6):483–491
32. Daniel WA, Wojcikowski J (1999b) The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol Appl Pharmacol 158(2):115–124
33. Davson H, Hollingsworth G, Segal MB (1970) The mechanism of drainage of the cerebrospinal fluid. Brain 93(4):665–678
34. Davson H, Segal MB (1995) Physiology of the CSF and blood–brain barriers. CRC Press, Boca Raton, USA
35. de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Annu Rev Pharmacol Toxicol 47:323–355
36. De Duve C (1970) The role of lysosomes in cellular pathology. Triangle 9(6):200–208
37. De Duve C (1971) Tissue fractionation. Past and present. J Cell Biol 50(1):20d–55d
38. de Duve C (1975) The role of lysosomes in the pathogeny of disease. Scand J Rheumatol Suppl 12:63–66
39. de Lange EC (2013a) The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS 10(1):12
40. de Lange EC (2013b) Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn 40(3):315–26
41. de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41(10):691–703
42. de Lange EC, de Boer BA, Breimer DD (1999) Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 36(2–3):211–227
43. de Lange EC, Ravenstijn PG, Groenendaal D, van Steeg TJ (2005) Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 7(3):E532–543
44. Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Beliveau R (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vascul Pharmacol 38(6):339–348
45. Deo AK, Theil FP, Nicolas JM (2013) Confounding parameters in preclinical assessment of blood–brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol Pharm 10(5):1581–95
46. Di L, Rong H, Feng B (2012a) Demystifying brain penetration in central nervous system drug discovery. J Med Chem 56(1):2–12
47. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE (2011) Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39(7):1270–1277
48. Di L, Umland JP, Trapa PE, Maurer TS (2012b) Impact of recovery on fraction unbound using equilibrium dialysis. J Pharm Sci 101(3):1327–1335
49. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33(1):165–174
50. Doran AC, Osgood SM, Mancuso JY, Shaffer CL (2012) An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos 40(11):2162–73
51. Dos-Anjos S, Martinez-Villayandre B, Montori S, Salas A, Perez-Garcia CC, Fernandez-Lopez A (2008) Quantitative gene expression analysis in a brain slice model: influence of temperature and incubation media. Anal Biochem 378(1):99–101
52. Duvvuri M, Krise JP (2005) A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol Pharm 2(6):440–448
53. Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P (2008) The burden of mental disorders. Epidemiol Rev 30:1–14
54. Elebring T, Gill A, Plowright AT (2012) What is the most important approach in current drug discovery: doing the right things or doing things right? Drug Discov Today 17(21–22): 1166–1169
55. Elmquist WF, Sawchuk RJ (1997) Application of microdialysis in pharmacokinetic studies. Pharm Res 14(3):267–288
56. Elmquist WF, Sawchuk RJ (2000) Use of microdialysis in drug delivery studies. Adv Drug Deliv Rev 45(2–3):123–124
57. Fenstermacher J, Kaye T (1988) Drug diffusion within the brain. Ann N Y Acad Sci 531:29–39
58. Fenstermacher JD (1992) The blood–brain barrier is not a “barrier” for many drugs. NIDA Res Monogr 120:108–120
59. Fichtl B, v Nieciecki A, Walter K (1991a) Tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. In: Testa B (ed) Advances in drug research , vol 20. Academic Press, London, pp 117–166
60. Fichtl B, Von Nieciecki A, Walter K (1991b) ChemInform abstract: tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. ChemInform 22
61. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U (2011) Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos 39(3):353–362
62. Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2009a) Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37(6):1226–1233
63. Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35(9):1711–1719
64. Friden M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M (2010) Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J Cereb Blood Flow Metab 30(1):150–161
65. Friden M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M (2009b) Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52(20):6233–6243
66. Fung EN, Chen YH, Lau YY (2003) Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 795(2):187–194
67. Gaillard PJ, de Boer AG (2000) Relationship between permeability status of the blood–brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 12(2):95–102
68. Gaillard PJ, Visser CC, Appeldoorn CC, Rip J (2012) Targeted blood-to-brain drug delivery – 10 key development criteria. Curr Pharm Biotechnol 13(12):2328–2339
69. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Oberg JO, Osterberg T (2005) In vitro models for the blood–brain barrier. Toxicol In Vitro 19(3):299–334
70. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P (2005) Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298(2):274–292
71. Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP (2012) Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci 3(1):50–68
72. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1(1):55–68
73. Gibaldi M (1969) Effect of mode of administration on drug distribution in a two-compartment open system. J Pharm Sci 58(3):327–331
74. Glees P, Voth D (1988) Clinical and ultrastructural observations of maturing human frontal cortex. Part I (Biopsy material of hydrocephalic infants). Neurosurg Rev 11(3–4):273–278
75. Gredell JA, Turnquist PA, Maciver MB, Pearce RA (2004) Determination of diffusion and partition coefficients of propofol in rat brain tissue: implications for studies of drug action in vitro. Br J Anaesth 93(6):810–817
76. Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M (2012) Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab 32(5):874–83
77. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M (2006) Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos 34(2):318–323
78. Hammarlund-Udenaes M (2010) Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106(3): 215–220
79. Hammarlund-Udenaes M, Bredberg U, Friden M (2009) Methodologies to assess brain drug delivery in lead optimization. Curr Top Med Chem 9(2):148–162
80. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25(8):1737–1750
81. Hammarlund-Udenaes M, Paalzow LK, de Lange EC (1997) Drug equilibration across the blood–brain barrier–pharmacokinetic considerations based on the microdialysis method. Pharm Res 14(2):128–134
82. Harashima H, Sugiyama Y, Sawada Y, Iga T, Hanano M (1984) Comparison between in-vivo and in-vitro tissue-to-plasma unbound concentration ratios (Kp, f) of quinidine in rats. J Pharm Pharmacol 36(5):340–342
83. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010) Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging 31(3):398–408
84. Hitchcock SA, Pennington LD (2006) Structure-brain exposure relationships. J Med Chem 49(26):7559–7583
85. Huang JD (1983) Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci 72(11):1368–1369
86. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 93(24):14164–14169
87. Jeffrey P, Summerfield SG (2007) Challenges for blood–brain barrier (BBB) screening. Xenobiotica 37(10–11):1135–1151
88. Kaitin KI, DiMasi JA (2011) Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 89(2):183–188
89. Kakee A, Terasaki T, Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood–brain barrier. J Pharmacol Exp Ther 277(3):1550–1559
90. Kakee A, Terasaki T, Sugiyama Y (1997) Selective brain to blood efflux transport of para-aminohippuric acid across the blood–brain barrier: in vivo evidence by use of the brain efflux index method. J Pharmacol Exp Ther 283(3):1018–1025
91. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23(8):327–338
92. Kalvass JC, Maurer TS, Pollack GM (2007a) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35(4):660–666
93. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM (2007b) Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323(1):346–355
94. Kariv I, Cao H, Oldenburg KR (2001) Development of a high throughput equilibrium dialysis method. J Pharm Sci 90(5):580–587
95. Kaufmann AM, Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 96(4):729–746
96. Kell DB, Dobson PD, Bilsland E, Oliver SG (2013) The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discov Today 18(5–6):218–239
97. Kell DB, Dobson PD, Oliver SG (2011) Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov Today 16(15–16):704–714
98. Kelly J (2009) Principles of CNS drug development: from test tube to clinic and beyond Kielbasa W, Stratford RE Jr (2012) Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug Metab Dispos 40(5):877–883
99. Klotz IM (1973) Physiochemical aspects of drug-protein interactions: a general perspective. Ann N Y Acad Sci 226:18–35
100. Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y (2011) Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood–brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 339(3):935–944
101. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Muhle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P (2011) Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One 6(8):e23852
102. Kurz H, Fichtl B (1983) Binding of drugs to tissues. Drug Metab Rev 14(3):467–510
103. Kusuhara H, Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78(1–3):43–54
104. Lee G, Dallas S, Hong M, Bendayan R (2001a) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53(4):569–596
105. Lee G, Schlichter L, Bendayan M, Bendayan R (2001b) Functional expression of P-glycoprotein in rat brain microglia. J Pharmacol Exp Ther 299(1):204–212
106. Li JY, Sugimura K, Boado RJ, Lee HJ, Zhang C, Duebel S, Pardridge WM (1999) Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. Protein Eng 12(9):787–796
107. Lin JH (2004) How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today (Barc) 40(1):5–22
108. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9(1):46–59
109. Lin JH, Sugiyama Y, Awazu S, Hanano M (1982) In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm 10(6):637–647
110. Lin TH, Lin JH (1990) Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J Pharmacol Exp Ther 253(1):45–50
111. Liu X, Chen C, Smith BJ (2008) Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 325(2):349–356
112. Liu X, Ding X, Deshmukh G, Liederer BM, Hop CE (2012) Use of cassette dosing approach to assess brain penetration in drug discovery. Drug Metab Dispos 40(5):963–9
113. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood–brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313(3):1254–1262
114. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34(9):1443–1447
115. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M (2009a) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37(4): 787–793
116. Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R (2009b) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37(7):1548–1556
117. Lloyd JB (2000) Lysosome membrane permeability: implications for drug delivery. Adv Drug Deliv Rev 41(2):189–200
118. Logan R, Funk RS, Axcell E, Krise JP (2012) Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opin Drug Metab Toxicol 8(8):943–958
119. Longhi R, Corbioli S, Fontana S, Vinco F, Braggio S, Helmdach L, Schiller J, Boriss H (2011) Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method. Drug Metab Dispos 39(2):312–321
120. Loryan I, Friden M, Hammarlund-Udenaes M (2013) The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS 10(1):6
121. MacIntyre AC, Cutler DJ (1988) The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 9(6):513–526
122. Manitpisitkul P, White RE (2004) Whatever happened to cassette-dosing pharmacokinetics? Drug Discov Today 9(15):652–658
123. Mano Y, Higuchi S, Kamimura H (2002) Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos 23(9):351–360
124. Maurer TS, Debartolo DB, Tess DA, Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33(1):175–181
125. McIlwain H (1951a) Glutamic acid and glucose as substrates for mammalian brain. J Ment Sci 97(409):674–680
126. McIlwain H (1951b) Metabolic response in vitro to electrical stimulation of sections of mammalian brain. Biochem J 48(4):1vi
127. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55(3):425–461
128. Muehlbacher M, Tripal P, Roas F, Kornhuber J (2012) Identification of drugs inducing phospholipidosis by novel in vitro data. ChemMedChem
129. Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y (2011) A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro 25(3):715–723
130. Ndengele MM, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM, Salvemini D (2009) Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 329(1):64–75
131. Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7(1):84–96
132. Newman GC, Hospod FE, Patlak CS (1988a) Brain slice glucose utilization. J Neurochem 51(6):1783–1796
133. Newman GC, Hospod FE, Schissel SL (1991) Ischemic brain slice glucose utilization: effects of slice thickness, acidosis, and K+. J Cereb Blood Flow Metab 11(3):398–406
134. Newman GC, Hospod FE, Wu P (1988b) Thick brain slices model the ischemic penumbra. J Cereb Blood Flow Metab 8(4):586–597
135. Nicholson C, Sykova E (1998) Extracellular space structure revealed by diffusion analysis. Trends Neurosci 21(5):207–215
136. Ohtsuki S, Takizawa T, Takanaga H, Hori S, Hosoya K, Terasaki T (2004) Localization of organic anion transporting polypeptide 3 (oatp3) in mouse brain parenchymal and capillary endothelial cells. J Neurochem 90(3):743–749
137. Ooie T, Terasaki T, Suzuki H, Sugiyama Y (1997) Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos 25(7):784–789
138. Padowski JM, Pollack GM (2011a) The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue. J Pharmacokinet Pharmacodyn 38(6):743–767
139. Padowski JM, Pollack GM (2011b) Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood–brain barrier P-glycoprotein effect. Brain Res 1426:1–17
140. Pardridge WM (1989) Strategies for drug delivery through the blood–brain barrier. Neurobiol Aging 10(5):636–637, discussion 648-650
141. Pardridge WM (1997) Drug delivery to the brain. J Cereb Blood Flow Metab 17(7):713–731
142. Pardridge WM (2006) Molecular Trojan horses for blood–brain barrier drug delivery. Curr Opin Pharmacol 6(5):494–500
143. Pardridge WM, Boado RJ, Black KL, Cancilla PA (1992) Blood–brain barrier and new approaches to brain drug delivery. West J Med 156(3):281–286
144. Patlak CS, Hospod FE, Trowbridge SD, Newman GC (1998) Diffusion of radiotracers in normal and ischemic brain slices. J Cereb Blood Flow Metab 18(7):776–802
145. Plise EG, Tran D, Salphati L (2010) Semi-automated protein binding methodology using equilibrium dialysis and a novel mixed-matrix cassette approach. J Pharm Sci 99(12):5070–5078
146. Raub TJL, Lutzke BS, Andrus PK, Sawada GA, Staton BA (2006) Early preclinical evaluation of brain exposure in support of hit identification and lead optimization. In: Borchardt RT, Middagh CR (eds) Optimization of drug-like properties during lead optimization, Biotechnology: pharmaceutical aspects series. Am Assoc Pharm Sci Press, Arlington, VA
147. Read KD, Braggio S (2010) Assessing brain free fraction in early drug discovery. Expert Opin Drug Metab Toxicol 6(3):337–344
148. Reichel A (2006) The role of blood–brain barrier studies in the pharmaceutical industry. Curr Drug Metab 7(2):183–203
149. Reichel A (2009) Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem Biodivers 6(11):2030–2049
150. Reichel A, Begley D, Abbott N (2003) An overview of in vitro techniques for blood–brain barrier studies. In: Nag S (ed) The blood–brain barrier: biology and research tools, Methods in molecular medicine (Vol. 89). Humana Press Inc., Totowa, NJ
151. Rice ME (1999) Use of ascorbate in the preparation and maintenance of brain slices. Methods 18(2):144–149
152. Rodgers T, Jones HM, Rowland M (2012) Tissue lipids and drug distribution: dog versus rat. J Pharm Sci 101(12):4615–4626
153. Romer J, Bickel MH (1979) A method to estimate binding constants at variable protein concentrations. J Pharm Pharmacol 31(1):7–11
154. Rouser G, Simon G, Kritchevsky G (1969) Species variations in phospholipid class distribution of organs. I. Kidney, liver and spleen. Lipids 4(6):599–606
155. Sargent DF, Bean JW, Schwyzer R (1988) Conformation and orientation of regulatory peptides on lipid membranes. Key to the molecular mechanism of receptor selection. Biophys Chem 31(1–2):183–193
156. Sargent DF, Schwyzer R (1986) Membrane lipid phase as catalyst for peptide-receptor interactions. Proc Natl Acad Sci U S A 83(16):5774–5778
157. Sawada Y, Hanano M, Sugiyama Y, Harashima H, Iga T (1984) Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J Pharmacokinet Biopharm 12(6):587–596
158. Scherrmann JM (2002) Drug delivery to brain via the blood–brain barrier. Vascul Pharmacol 38(6):349–354
159. Schoepp DD (2011) Where will new neuroscience therapies come from? Nat Rev Drug Discov 10(10):715–716
160. Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying lysosomal storage diseases. Trends Neurosci 34(8):401–410
161. Schwab ME, Buchli AD (2012) Drug research: plug the real brain drain. Nature 483(7389): 267–268
162. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S (2008) High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7(10):4266–4277
163. Segall MD (2012) Multi-parameter optimization: identifying high quality compounds with a balance of properties. Curr Pharm Des 18(9):1292–1310
164. Shaffer CL (2010) Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships. Annu Rep Med Chem 45:55–70
165. Shen DD, Artru AA, Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56(12): 1825–1857
166. Simon G, Rouser G (1969) Species variations in phospholipid class distribution of organs. II. Heart and skeletal muscle. Lipids 4(6):607–614
167. Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9(12):929–939
168. Smith QR (1991) The blood–brain barrier and the regulation of amino acid uptake and availability to brain. Adv Exp Med Biol 291:55–71
169. Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de Lange EC (2012) Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn 39(5):463–477
170. Stokes CE, Murphy D, Paton JF, Kasparov S (2003) Dynamics of a transgene expression in acute rat brain slices transfected with adenoviral vectors. Exp Physiol 88(4):459–466
171. Su TZ, Lunney E, Campbell G, Oxender DL (1995) Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem 64(5):2125–2131
172. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322(1):205–213
173. Summerfield SG, Stevens AJ, Cutler L, del Carmen OM, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316(3):1282–1290
174. Sun N, Avdeef A (2011) Biorelevant pK(a) (37 degrees C) predicted from the 2D structure of the molecule and its pK(a) at 25 degrees C. J Pharm Biomed Anal 56(2):173–182
175. Sykova E (2004) Extrasynaptic volume transmission and diffusion parameters of the extracellular space. Neuroscience 129(4):861–876
176. Sykova E, Nicholson C (2008) Diffusion in brain extracellular space. Physiol Rev 88(4): 1277–1340
177. Syvanen S, Hooker A, Rahman O, Wilking H, Blomquist G, Langstrom B, Bergstrom M, Hammarlund-Udenaes M (2008) Pharmacokinetics of P-glycoprotein inhibition in the rat blood–brain barrier. J Pharm Sci 97(12):5386–5400
178. Syvanen S, Lindhe O, Palner M, Kornum BR, Rahman O, Langstrom B, Knudsen GM, Hammarlund-Udenaes M (2009) Species differences in blood–brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37(3):635–643
179. Syvanen S, Schenke M, van den Berg DJ, Voskuyl RA, de Lange EC (2012) Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate. AAPS J 14(1):87–96
180. Tanaka H, Mizojiri K (1999) Drug-protein binding and blood–brain barrier permeability. J Pharmacol Exp Ther 288(3):912–918
181. Terasaki T, Hosoya K (1999) The blood–brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 36(2–3):195–209
182. Terasaki T, Ohtsuki S (2005) Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood–brain barrier: an overview of biology and methodology. NeuroRx 2(1):63–72
183. Thorne RG, Emory CR, Ala TA, Frey WH 2nd (1995) Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692(1–2):278–282
184. Thorne RG, Hrabetova S, Nicholson C (2004) Diffusion of epidermal growth factor in rat brain extracellular space measured by integrative optical imaging. J Neurophysiol 92(6):3471–3481
185. Thorne RG, Lakkaraju A, Rodriguez-Boulan E, Nicholson C (2008) In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc Natl Acad Sci U S A 105(24):8416–8421
186. Thorne RG, Nicholson C (2006) In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A 103(14):5567–5572
187. Tsuji A, Tamai I, Sakata A, Tenda Y, Terasaki T (1993) Restricted transport of cyclosporin A across the blood–brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 46(6):1096–1099
188. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51(18):1427–1437
189. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T (2011a) Blood–brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339(2):579–588
190. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T (2011b) Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. J Neurochem 117(2):333–345
191. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y (2009) Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 877(23):2198–2207
192. van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R (2011) Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. J Lab Autom 16(1):56–67
193. Van Peer AP, Belpaire FM, Bogaert MG (1981) Binding of drugs in serum, blood cells and tissues of rabbits with experimental acute renal failure. Pharmacology 22(2):146–152
194. Vauquelin G, Bostoen S, Vanderheyden P, Seeman P (2012) Clozapine, atypical antipsychotics, and the benefits of fast-off D(2) dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 385(4):337–372
195. Vauquelin G, Packeu A (2009) Ligands, their receptors and … plasma membranes. Mol Cell Endocrinol 311(1–2):1–10
196. Vauquelin G, Van Liefde I (2005) G protein-coupled receptors: a count of 1001 conformations. Fundam Clin Pharmacol 19(1):45–56
197. Vuignier K, Schappler J, Veuthey JL, Carrupt PA, Martel S (2010) Drug-protein binding: a critical review of analytical tools. Anal Bioanal Chem 398(1):53–66
198. Wager TT, Liras JL, Mente S, Trapa P (2012) Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling. Expert Opin Drug Metab Toxicol 8(5): 531–542
199. Wan H, Ahman M, Holmen AG (2009) Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. J Med Chem 52(6):1693–1700
200. Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50(19):4606–4615
201. Wang Y, Welty DF (1996) The simultaneous estimation of the influx and efflux blood–brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm Res 13(3):398–403
202. Wang YY, Lui PC, Li JY (2009) Receptor-mediated therapeutic transport across the blood–brain barrier. Immunotherapy 1(6):983–993
203. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD (2009) Receptor occupancy and brain free fraction. Drug Metab Dispos 37(4):753–760
204. Weaver DF, Weaver CA (2011) Exploring neurotherapeutic space: how many neurological drugs exist (or could exist)? J Pharm Pharmacol 63(1):136–139
205. Wellmann H, Kaltschmidt B, Kaltschmidt C (1999) Optimized protocol for biolistic transfection of brain slices and dissociated cultured neurons with a hand-held gene gun. J Neurosci Methods 92(1–2):55–64
206. Westerhout J, Danhof M, De Lange EC (2011) Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci 100(9): 3577–3593
207. Westerhout J, Ploeger B, Smeets J, Danhof M, de Lange EC (2012) Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J 14(3):543–553
208. Wolak D, Thorne R (2013) Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm 10(5):1492–504
209. Yokogawa K, Ishizaki J, Ohkuma S, Miyamoto K (2002) Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find Exp Clin Pharmacol 24(2):81–93
210. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE et al (1988) Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem 31(3):656–671
211. Zhao R, Kalvass JC, Pollack GM (2009) Assessment of blood–brain barrier permeability using the in situ mouse brain perfusion technique. Pharm Res 26(7):1657–1664